Anticancer effect and safety of doxorubicin and nutraceutical sulforaphane liposomal formulation in triple-negative breast cancer (TNBC) animal model

• DOI: 10.1016/j.biopha.2023.114490
• Publication Date: 2023-03-15T11:35:46Z
• Authors: Anna Pogorzelska; Maciej Mazur; Marta Świtalska; Joanna Wietrzyk; Dawid Sigorski; Krzysztof Fronczyk; Katarzyna Wiktorska
• Keywords: Sulforaphane; Triple-negative breast cancer

Female breast cancer is the most deadly in women worldwide. The triple-negative subtype therapies, due to lack of specific drug targets, are still based on systemic chemotherapy with doxorubicin, which burdened severe adverse effects. To enhance therapeutic success and protect against toxicity, carriers or combination therapy being developed. Thus, an innovative liposomal formulation containing doxorubicin main nutraceutical, sulforaphane, has been anticancer efficacy safety proposed was evaluated vivo, a 4T1 mouse model cancer, mechanism action determined vitro, using MDA-MB-231 non-tumorigenic MCF-10A cell line. elaborated were shown efficiently deliver both compounds into direct nucleus. Incorporation sulforaphane resulted twofold inhibition tumor growth potential up fourfold reduction concentration synergistic interaction between two compounds. Sulforaphane increase accumulation nuclei cells, accompanied by mitosis, without affecting reactive oxygen species status cell. In normal antagonistic effect resulting less cytotoxicity observed. vivo results showed that incorporation yielded not only cardioprotective, but also nephro- hepatoprotective research revealed prospects applying as component chemotherapy.